These findings highlight the PRD’s contribution to HD toxicity and point to MKL2/MRTFB and the cytoskeleton and transcriptional coactivator MKL2/MRTFB and the cytoskeleton as candidate mediators.
Abstract
The Huntingtin gene (HTT) contains a conserved, yet expandable CAG repeat within exon 1. While the pathogenic expansion in Huntington’s Disease (HD) is well studied, the role of surrounding domains remains unclear. Using genome-edited mini-organoids and neurons, we dissected HTT exon 1 and found species-specific toxicity: the human variant caused more severe deficits than the mouse. Swapping the proline-rich domain (PRD) - the most divergent region - revealed its key role: the mouse PRD mitigated, while the human PRD worsened neuronal phenotypes. Omics profiling showed that pathogenic human exon 1 induced broad protein dysregulation, largely reversed by mouse PRD replacement. Bioinformatics implicated the actin cytoskeleton and transcriptional coactivator MKL2/MRTFB. We validated MKL2/MRTFB dysregulation in HD models and showed that restoring its expression rescued neuronal abnormalities. These findings highlight the PRD’s contribution to HD toxicity and point to MKL2/MRTFB and the cytoskeleton as candidate mediators.
It is shown that the proline‑rich domain regulates HTT1a transcript production via mRNA structure and SRSF7 binding, revealing sequence context-dependent control of toxic HTT generation.
Camilla Maffezzini, R. Iennaco, Andrea Scolz et al.· Nature Communications· 0 citations
A previously unrecognized modulatory role of wt-C9orf72 in regulating mHTT aggregation in experimental HD models is identified and a novel wt-C9orf72-Stat1-Isg15 axis is identified, providing new insights into wt-C9orf72-associated protein homeostasis.
Through targeted genetic knock-down, huntingtin is identified as a cell-autonomous regulator of neuropeptide trafficking, neuronal excitability and circadian output and carries direct relevance for HD therapeutic strategies, particularly those involving huntingtin-lowering approaches.
These findings position somatic expansion as a promising therapeutic target and demonstrate the potential of RNAi-based cosilencing of MSH3 and HTT as a disease-modifying strategy for HD.
Jillian Belgrad, Ashley Summers, C. Landles et al.· Science Translational Medici...· 0 citations
It is demonstrated that ENAH–PRD interactions modulate HTT1a aggregation dynamics and the framework for investigating how EVH1-containing proteins may influence HTT1a proteostasis and neurotoxicity in Huntington′s disease is established.
A comprehensive evaluation of the VPS35 protein interactome is provided and a selective effect of the PD-linked D620N mutation in mammalian cells and brain is revealed, providing key insight into the mechanisms of retromer dysfunction in VPS35-linked PD.
Erin T. Williams, Maxwell Frye, Xi Chen et al.· Neurobiology of Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.